Program
Yellow Fever Vaccine
Also written as “Yellow fever vaccine (produced on serum-free Vero cells)”, “Yellow fever vaccine (live)” and “Yellow Fever vaccine”.
Its studies are mostly in Yellow Fever · Measles · Severe Dengue · Malaria · Streptococcal Infections, led by 4 companies.
Drug pageYellow Fever Vaccine: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 62 open or running | phase 3since Sep 7, 2011 | Sep 21, 2009 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 3since Feb 23, 2016 | Dec 2, 2010 | none ahead |
| Novartisits history only | 10 open or running | phase 3since Nov 3, 2011 | Nov 3, 2011 | none ahead |
| Sinopharmits history only | 10 open or running | phase 3since Apr 30, 2024 | Apr 30, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 21, 2009First study: phase 2 study in Encephalitis, JapaneseFirst studyNCT00982137 · 108 enrolled · Australia
- Sep 7, 2011Phase 3 study in DengueNCT01436396 · 792 enrolled · Colombia, Peru
- Jun 25, 2021Phase 2 study in Yellow FeverNCT04942210 · 568 enrolled · United States
- Aug 17, 2021Phase 2 study in Yellow FeverNCT05011123 · 690 enrolled · Finland, France, Germany and more
- May 23, 2025Phase 3 study in Yellow FeverNCT07002060 · 640 enrolled · United States
- Oct 27, 2025Phase 3 study in Yellow FeverNCT07222059 · 254 enrolled · Japan
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 6 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07222059Yellow Fever · Japan | 3 | Completed | Dec 25, 2025 | 254 |
| NCT07002060Yellow Fever · United States | 3 | Completed | Jan 20, 2026 | 640 |
| NCT05011123Yellow Fever · Finland, France, Germany and more | 2 | Active, not recruiting | May 23, 2022 | 690 |
| NCT04942210Yellow Fever · United States | 2 | Active, not recruiting | Jun 24, 2022 | 568 |
| NCT01436396Dengue · Colombia, Peru | 3 | Completed | Sep 2013 | 792 |
| NCT00982137Encephalitis, Japanese · Australia | 2 | Completed | Apr 2005 | 108 |
How it is read
Names in the registry
- “Yellow fever vaccine (produced on serum-free Vero cells)”, 2 entries
- “Yellow fever vaccine (live)”, 2 entries
- “Yellow Fever Vaccine”, 2 entries
- “Yellow Fever vaccine”, 1 entry
- “YF vaccine (live)”, 1 entry
Conditions, from the studies’ own filings
- Yellow Fever, 4 studies
- Measles, 1 study
- Severe Dengue, 1 study
- Malaria, 1 study
- Streptococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.